Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Endocrine Disorders and Peripheral Arterial Disease: A Series of Reviews

Author(s): Pavel Poredoš*, Gerit Holger Schernthaner, Ales Blinc, Dimitri P. Mikhailidis, Pier Luigi Antignani, Panagiotis G. Anagnostis, Mojca Jensterle, Katica Bajuk Studen, Miso Šabović and Mateja Kaja Jezovnik

Volume 21, Issue 3, 2023

Published on: 31 May, 2023

Page: [147 - 148] Pages: 2

DOI: 10.2174/1570161121666230516141319

Price: $65

« Previous Next »
[1]
Aronow WS. Peripheral arterial disease in the elderly. Clin Interv Aging 2007; 2(4): 645-54.
[PMID: 18225466]
[2]
Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: Morbidity and mortality implications. Circulation 2006; 114(7): 688-99.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.593442] [PMID: 16908785]
[3]
Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol 2020; 76(25): 2982-3021.
[http://dx.doi.org/10.1016/j.jacc.2020.11.010] [PMID: 33309175]
[4]
Giudice R, Izzo R, Manzi MV, et al. Lifestyle-related risk factors, smoking status and cardiovascular disease. High Blood Press Cardiovasc Prev 2012; 19(2): 85-92.
[PMID: 22867094]
[5]
Hoek AG, van Oort S, Elders PJM, Beulens JWJ. Causal association of cardiovascular risk factors and lifestyle behaviors with peripheral artery disease: A mendelian randomization approach. J Am Heart Assoc 2022; 11(16): e025644.
[http://dx.doi.org/10.1161/JAHA.122.025644] [PMID: 35929454]
[6]
Ramezankhani A, Azizi F, Hadaegh F, Eskandari F. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: A population-based prospective study. Atherosclerosis 2017; 263: 249-56.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.921] [PMID: 28683364]
[7]
Roever L, Biondi-Zoccai G, Rao SV. Lipid-lowering therapy in patients with high cardiovascular risk: Dose or combination? Clin Ther 2017; 39(3): 659-60.
[http://dx.doi.org/10.1016/j.clinthera.2017.01.029] [PMID: 28190598]
[8]
Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: Hormonal and biochemical influences. Reprod Sci 2010; 17(6): 511-31.
[http://dx.doi.org/10.1177/1933719110367829] [PMID: 20460551]
[9]
Armstrong EJ, Waldo SW, Valle JA. The heart and vascular team. J Am Coll Cardiol 2018; 72(25): 3285-6.
[http://dx.doi.org/10.1016/j.jacc.2018.10.032] [PMID: 30573031]
[10]
Vila G, Jørgensen JOL, Luger A, Stalla GK. Insulin resistance in patients with acromegaly. Front Endocrinol 2019; 10: 509.
[http://dx.doi.org/10.3389/fendo.2019.00509] [PMID: 31417493]
[11]
Papadopoulou AM, Bakogiannis N, Skrapari I, Moris D, Bakoyiannis C. Thyroid dysfunction and atherosclerosis: A systematic review. In Vivo 2020; 34(6): 3127-36.
[http://dx.doi.org/10.21873/invivo.12147] [PMID: 33144416]
[12]
van der Sluis RJ, Hoekstra M. Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease. Mol Cell Endocrinol 2020; 504: 110728.
[http://dx.doi.org/10.1016/j.mce.2020.110728] [PMID: 31968221]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy